This acquisition encompasses two owned bars in Brisbane and three franchised locations in Victoria, New

The post Tilray Brands expands global footprint; closes acquisition of BrewDog Brewing Australia appeared first on Up2info.com.

The post Tilray Brands, Carlsberg Group form exclusive multi-year U.S. brewing partnership appeared first on Up2info.com.

{{ratings_table}}

{{quant_chart}}

The post Warning: TLRY is at high risk of performing badly appeared first on Up2info.com.

The post Tilray Medical expands in Italy with Tilray Medical Italia launch appeared first on Up2info.com.

Management View

• CEO Irwin Simon reported, “We delivered a strong second quarter marked by record results and a beat against analyst expectations in the face of strong headwinds. We recorded our highest ever Q2 net revenue of $218 million, achieved an adjusted EBITDA of $8.4 million, and a reported reverse stocks with adjusted EPS loss of $0.02, all while generating an adjusted cash operating income of $6 million.” Simon emphasized sequential growth in international cannabis revenue, year-over-year improvements in net income and free cash flow, and a reduction in debt leading to a net cash position exceeding debt by almost $30 million.
• Simon detailed Tilray’s operations in more than 20 countries and highlighted its leadership in Canadian cannabis production, craft beer brewing in the U.S., and branded hemp wellness products in North America. He stated, “Global cannabis revenue increased to $68 million, our high-margin international cannabis business led the growth, increasing 36% year-over-year and 51% substantially to $20 million, marking one of our strongest international quarters to date.”
• Simon discussed strategic readiness for U.S. regulatory changes, stating, “The decision by President Trump to federally reschedule cannabis in the U.S. represents one of the most consequential regulatory shifts that the industry has seen in decades. This is a moment Tilray has been preparing for methodically for years. And guess what, we are ready to go.”
• Expansion in Europe, particularly Germany, the U.K., and Poland, was identified as a significant growth opportunity. Simon said, “Tilray Medical is expected to generate approximately $150 million in revenue on an annual run rate.”
• Simon highlighted the beverage business’s revenue of $50 million and ongoing integration and cost-saving efforts, reporting, “We delivered $27 million in annualized cost savings in the first half of the year and remain on track towards our $33 million target.”
• CFO Carl Merton stated, “We are reporting record second quarter net revenue and strong year-over-year improvements in profitability, and we are reaffirming our full year 2026 adjusted EBITDA guidance. Net revenue for the quarter was a record $217.5 million.”

Outlook

• Management reaffirmed full year 2026 adjusted EBITDA guidance of $62 million to $72 million.
• Simon indicated continued momentum in international cannabis and distribution, ongoing cost-saving initiatives in beverage, and a focus on commercial expansion in Europe, especially Germany.
• In reference to U.S. regulatory changes, Simon said, “We are ready to produce and sell as we’re currently operating a leading THC beverage operation across Canada with over 45% of the THC beverage market share.”

Financial Results

• Net revenue for the quarter was $217.5 million, with cannabis net revenue at $67.5 million, driven by a 36% increase in international cannabis and a 6% increase in Canadian adult-use cannabis.
• Beverage net revenue reached $50.1 million, impacted by “category-wide headwinds in the craft beer segment and our own portfolio optimization efforts under Project 420.”
• Distribution net revenue increased 26% year-over-year to $85.3 million.
• Gross profit was $57.5 million with an overall gross margin of 26%. Cannabis gross margin increased to 39% from 35% last year, distribution margin rose to 13%, and wellness margin to 32%.
• Net loss for the quarter was $43.5 million, a 49% improvement year-over-year.
• Cash and marketable securities ended at $291.6 million, and the company achieved a net cash position of almost $30 million.

Q&A

• William Kirk, ROTH Capital: Asked about regulatory outcomes on intoxicating hemp bans and supply strategy. Simon responded, “We are working with some congressmen, senators, lobbyists to either extend the deadline or to change some of the regulatory that would have a regulated amount of milligrams.” Merton explained the redeployment of supply from Canadian wholesale to higher-margin international markets.
• Xin Ma, TD Cowen: Inquired about Canadian adult-use cannabis growth and distribution sales drivers. Simon indicated volume-driven growth and noted, “We did gain a little bit of share, not a lot in the quarter.”
• Aaron Grey, Alliance Global Partners: Requested details on the timing for Tilray Global Medical to approach $150 million and risks in Germany. Simon stated, “Right now, we’re on a run rate for that $150 million…the majority of that is coming from international markets.”
• Pablo Zuanic, Zuanic & Associates: Sought clarity on CC Pharma expansion and beverage business strategy. Simon said, “We have focused on that business…there is a big focus to use that sales organization to sell more and more cannabis — medical cannabis in Germany.”
• Frederico Yokota Gomes, ATB Capital: Questioned the impact of U.S. rescheduling on state-legal cannabis investments. Simon responded, “Tilray is committed to invest in research…but it’s not state-by-state where we’re looking at recreational. We are totally looking at this from a total medical standpoint.”

Sentiment Analysis

• Analysts posed probing questions about regulatory risks, supply strategy, and growth drivers, with a neutral to slightly positive tone as they sought clarity on growth prospects and risk mitigation.
• Management maintained a confident and optimistic tone in both prepared remarks and Q&A, frequently referencing readiness, strategic positioning, and cost discipline. Simon stated, “We are confident in Tilray’s trajectories for the second half of fiscal 2026 and beyond.”
• Compared to the previous quarter, analyst tone remained similar, but management’s tone shifted to a more assertive stance on international expansion and readiness for regulatory changes.

Quarter-over-Quarter Comparison

• Compared to Q1, Q2 featured a stronger emphasis on international cannabis growth, with international cannabis revenue increasing 36% year-over-year and 51% sequentially.
• The company progressed from a net income of $1.5 million in Q1 to a net loss of $43.5 million in Q2, though management highlighted improved year-over-year profitability and cash flow.
• Strategic focus shifted toward leveraging regulatory changes in the U.S. and Europe, with heightened attention on medical cannabis and pharmaceutical distribution expansion.
• Analyst focus moved from supply chain risks and regulatory uncertainties to questions about execution, risk management, and long-term positioning.
• Management’s confidence increased, supported by stronger liquidity and improved operational performance.

Risks and Concerns

• Management acknowledged ongoing regulatory uncertainty in the U.S. hemp-derived THC beverage market and potential post-2026 changes.
• Price compression in international markets, especially Germany, and ongoing permit challenges in Portugal and Germany were cited.
• The beverage segment faced industry-wide headwinds and margin pressures, though cost initiatives are underway.
• Simon highlighted the need for Canadian regulatory modernization to maintain competitiveness and avoid losing value creation to international markets.

Final Takeaway

Tilray’s second quarter showcased record net revenue and robust international cannabis growth, supported by a strengthened balance sheet and strategic positioning for regulatory changes in key markets. Management reiterated a focus on medical cannabis expansion, operational efficiencies, and leveraging its diversified platform to capitalize on evolving global opportunities across cannabis, beverage, and wellness segments, with a particular emphasis on achieving a $150 million global medical cannabis run rate and reaffirmed adjusted EBITDA guidance for fiscal 2026.

Read the full Earnings Call Transcript

The post Tilray anticipates $150M global medical cannabis revenue run rate as international expansion accelerates appeared first on Up2info.com.

The post Tilray rises as it achieves record quarterly revenue on cannabis sales growth appeared first on Up2info.com.

The post Tilray in charts: Cannabis business inches up 3% Y/Y appeared first on Up2info.com.

The post Earnings Snapshot: Tilray posts record quarterly revenue of $217.51M appeared first on Up2info.com.

The post Tilray Non-GAAP EPS of -$0.02, revenue of $217.51M beats by $6.36M appeared first on Up2info.com.

Wall Street estimates the Canadian cannabis player to post EPS -$0.14. The revenue consensus stands at $211.15 million, representing a 0.1% Y/Y improvement.

Over the last 2 years, TLRY has beaten EPS estimates 75% of the time and has beaten revenue estimates 38% of the time. However, as per Zacks Equity Research, the company may not continue the trend this quarter.

They have projected Tilray’s quarterly earnings to project underlying weaknesses, including margin pressures across core segments. The company’s overall margins have been facing pressures due to weak margins in the Beverage and Cannabis segments, it noted. Craft brands and spirits businesses have also faced ongoing challenges, Zacks added.

“Although the beverage segment has been soft-impacted by ongoing SKU rationalization, the company is focused on its turnaround. It is making progress against the beer integration, optimizing strategy and Project 420 initiative. Management sees potential for the beverage category based on the diversification of offerings and the superior products with improved operations, leveraged acquired brands and supporting performance,” Zacks said.

Investors will also be keenly watching out for developments over U.S. President Donald Trump’s executive order to reclassify marijuana as a Schedule III substance (or a less dangerous drug). They will also be monitoring for commentary on rescheduling, tax relief and the new Tilray Medical USA subsidiary.

On December 13, Tilray’s stock closed ~65% higher, registering its best weekly gain ever. On a YTD basis, however, it has risen by only 2.55% compared to a 1.45% rise in the broader markets.

The post Tilray Brands Q2 preview: Bottom line weakness to persist but reclassification offers hope appeared first on Up2info.com.